slc5a9 Antibody

What is SLC5A9 and why is it important in research?

SLC5A9, also known as sodium-glucose linked transporter 4 (SGLT4), is a sodium-dependent glucose cotransporter encoded by the SLC5A9 gene in humans. It functions as an electrogenic Na⁺-coupled sugar symporter that plays a primary role in D-mannose transport and possibly D-fructose and D-glucose transport at the plasma membrane. Its transporter activity is driven by a transmembrane Na⁺ electrochemical gradient established by the Na⁺/K⁺ pump. SLC5A9 distinctively recognizes sugar substrates containing a pyranose ring with an axial hydroxyl group on carbon 2, making it an important target for understanding specialized sugar transport mechanisms . Research on SLC5A9 contributes to our understanding of glucose homeostasis, metabolic disorders, and potential therapeutic targets for conditions like diabetes and metabolic syndrome.

What applications are SLC5A9 antibodies commonly used for?

SLC5A9 antibodies are utilized across multiple experimental applications in research settings. Based on commercial availability and validation data, these antibodies are primarily recommended for:

• Western Blotting (WB): For protein expression analysis and semi-quantitative measurement of SLC5A9 levels in tissue or cell lysates

• Enzyme-Linked Immunosorbent Assay (ELISA): For quantitative detection of SLC5A9 protein

• Immunohistochemistry (IHC): Particularly for formalin-fixed, paraffin-embedded (FFPE) tissues, allowing localization studies of SLC5A9 expression in human tissues such as skin and brain (cerebellum)

• Immunofluorescence labeling: For visualizing SLC5A9 distribution in cells and tissues

The selection of application should be guided by the specific research question and the validation profile of the particular antibody being used.

What species reactivity is available for SLC5A9 antibodies?

SLC5A9 antibodies demonstrate varying cross-reactivity profiles depending on the specific product and the epitope targeted. From the available information, the reactivity profiles include:

• Human-specific: Most commercially available SLC5A9 antibodies are validated for human samples

• Multi-species reactivity: Some antibodies show cross-reactivity with samples from:

  • Mouse

  • Rat

  • Monkey

  • Horse

  • Gorilla

When selecting an antibody for cross-species experiments, it is crucial to verify the homology of the immunogen sequence between species. For instance, one antibody was raised against a synthetic peptide derived from the N-terminal extracellular region of human SGLT4 protein, which showed only 61.1% homology to mouse or rat sequences , potentially affecting antibody performance in these species.

What are the different types of SLC5A9 antibodies available for research?

Researchers have access to several types of SLC5A9 antibodies that vary in their targeted epitopes and applications:

• Full-length antibodies: Targeting the complete SLC5A9 protein

• Domain-specific antibodies:

  • N-terminal domain antibodies: Targeting the N-terminal extracellular region of SLC5A9

  • C-terminal domain antibodies: Targeting the C-terminal region

  • Cytoplasmic domain antibodies: Targeting intracellular portions of the protein

  • Mid-region antibodies: Targeting specific amino acid sequences (e.g., AA 230-320)

The current commercial landscape predominantly features rabbit polyclonal antibodies for SLC5A9, which are produced through immunization with synthetic peptides derived from human SLC5A9 sequences . These antibodies are typically unconjugated and purified using antigen affinity purification methods to enhance specificity.

How do I optimize Western blot conditions for SLC5A9 antibody detection?

Optimizing Western blot protocols for SLC5A9 detection requires attention to several technical parameters:

Sample Preparation:

• Use appropriate extraction buffers containing protease inhibitors to prevent degradation of the transporter protein

• Consider membrane protein extraction protocols, as SLC5A9 is a transmembrane protein

• Avoid excessive heating of samples, which can cause aggregation of membrane proteins

Gel Electrophoresis and Transfer:

• Use 8-10% polyacrylamide gels for optimal resolution of the SLC5A9 protein

• Consider wet transfer systems for more efficient transfer of larger membrane proteins

• Use PVDF membranes rather than nitrocellulose for higher protein retention

Antibody Concentration and Incubation:

• Start with recommended dilutions (e.g., 1:1000 for Western blot) and adjust based on signal intensity

• Test different antibody concentrations to avoid high background or weak signals

• Optimize blocking conditions to reduce non-specific binding

• Consider overnight primary antibody incubation at 4°C to enhance specific binding

Detection and Controls:

• Include positive controls from tissues known to express SLC5A9

• Use appropriate negative controls to validate specificity

• Consider the use of loading controls that are suitable for membrane proteins

What are the critical parameters for successful immunohistochemistry with SLC5A9 antibodies?

Immunohistochemical detection of SLC5A9 requires optimization of several key parameters:

Antigen Retrieval:

• For formalin-fixed, paraffin-embedded tissues, heat-induced epitope retrieval is typically necessary

• Test both citrate buffer (pH 6.0) and EDTA buffer (pH 9.0) to determine optimal conditions

Antibody Selection and Concentration:

• Choose antibodies specifically validated for IHC applications

• Use recommended working concentrations (e.g., 10 μg/ml as used in validated protocols)

• Perform antibody titration to determine optimal concentration for your specific tissues

Detection Systems:

• Select appropriate secondary antibodies and detection systems based on desired sensitivity

• Consider signal amplification systems for low-abundance targets

Tissue Selection:

• Based on available data, human skin and brain (cerebellum) tissues have been successfully used for SLC5A9 immunohistochemistry

• Include positive control tissues with known SLC5A9 expression

Controls and Validation:

• Include isotype controls to assess non-specific binding

• Consider peptide competition assays to confirm antibody specificity

• When possible, validate IHC results with complementary methods like in situ hybridization

How can I troubleshoot high background in SLC5A9 ELISA applications?

High background signals in ELISA using SLC5A9 antibodies can result from multiple factors. A systematic troubleshooting approach includes:

Blocking Optimization:

• Test different blocking buffers if the current one is ineffective

• Consider adding blocking reagent to wash buffer to reduce non-specific binding

• Use 5-10% serum from the same species as the secondary antibody to minimize cross-reactivity

Antibody Dilution Adjustment:

• High antibody concentration often leads to increased background

• Perform serial dilutions to determine optimal working concentration

• For detection reagents, ensure proper dilution according to manufacturer recommendations

Washing Procedures:

• Insufficient washing is a common cause of high background

• Increase the number and/or duration of wash steps

• Ensure consistent and thorough washing of all wells

Buffer Composition:

• Increasing salt concentration in incubation and wash buffers may reduce non-specific interactions

• Avoid sodium azide in wash buffers when using HRP-conjugated reagents

Technical Considerations:

• Perform substrate incubation in the dark to prevent light-induced background

• Read plates immediately after adding stop solution to avoid signal drift

• Ensure clean plate bottoms before reading

What cellular localization pattern should I expect when using SLC5A9 antibodies?

SLC5A9 is a transmembrane protein functioning as a sodium-glucose cotransporter at the plasma membrane. When using antibodies targeting different domains of this protein, researchers should consider the following localization patterns:

Plasma Membrane Localization:

• Primary localization should be at the cell surface, particularly in polarized cells

• In transport-active tissues, SLC5A9 may show apical or basolateral distribution depending on the cell type

Domain-Specific Considerations:

• Antibodies targeting the N-terminal extracellular domain are ideal for cell-surface staining in non-permeabilized cells

• Antibodies against cytoplasmic domains require cell permeabilization for access to the epitope

• C-terminal antibodies may detect both membrane-integrated and processing intermediates of the protein

Tissue-Specific Expression:

• Successful immunohistochemical detection has been reported in human skin and brain (cerebellum) tissues

• Expression patterns may vary across tissues based on physiological requirements for mannose and fructose transport

For accurate interpretation of localization studies, researchers should compare results using antibodies targeting different domains of the protein and validate findings with complementary approaches such as gene expression analysis or functional transport assays.

What are the recommended sample preparation protocols for detecting SLC5A9 in different applications?

Sample preparation is critical for successful detection of SLC5A9 across different experimental platforms:

For Western Blotting:

• Cell Lysates: Use RIPA buffer supplemented with protease inhibitors

• Tissue Homogenates: Homogenize in membrane protein extraction buffer containing 1% NP-40 or Triton X-100

• Membrane Fraction Isolation: Consider sucrose gradient ultracentrifugation for enrichment of membrane proteins

• Sample Denaturation: Heat at 70°C rather than 95°C to minimize membrane protein aggregation

For Immunohistochemistry:

• Fixation: 10% neutral buffered formalin is standard for most tissues

• Embedding: Paraffin embedding using standard protocols

• Sectioning: 4-6 μm sections are optimal for most applications

• Antigen Retrieval: Test both heat-mediated retrieval methods with different pH buffers

For ELISA:

• Protein Extraction: Use buffers compatible with the specific ELISA format

• Sample Dilution: Prepare multiple dilutions to ensure readings within the linear range

• Matrix Effects: Consider the impact of sample matrix on antibody binding

• Pre-treatment: Evaluate the need for sample pre-treatment to expose epitopes

How should I validate the specificity of SLC5A9 antibodies for my research?

Comprehensive validation of SLC5A9 antibodies should include multiple complementary approaches:

Positive and Negative Controls:

• Positive Controls: Include samples with known SLC5A9 expression

• Negative Controls: Use samples from knockout models or tissues known not to express SLC5A9

• Isotype Controls: Include appropriate isotype antibodies to assess non-specific binding

Peptide Competition Assays:

• Pre-incubate antibody with the immunizing peptide

• Compare staining between blocked and unblocked antibody

• Specific signals should be significantly reduced or eliminated by peptide competition

Multiple Antibody Comparison:

• Test antibodies targeting different epitopes of SLC5A9

• Consistent detection across antibodies increases confidence in specificity

Complementary Techniques:

• Correlate protein detection with mRNA expression (RT-PCR or in situ hybridization)

• Confirm functional relevance through transport assays or other functional studies

• Consider knockdown/knockout validation where feasible

Western Blot Analysis:

• Verify single band of expected molecular weight

• Analyze band pattern across different tissue types

• For polyclonal antibodies, compare lot-to-lot consistency

What are the recommended dilutions and incubation conditions for SLC5A9 antibodies?

Optimal working conditions vary by application and specific antibody. Based on available information:

Western Blotting:

• Starting Dilution: 1:1000 is commonly recommended

• Incubation: Overnight at 4°C for primary antibody

• Secondary Antibody: 1-2 hour incubation at room temperature

Immunohistochemistry:

• Working Concentration: 10 μg/ml has been validated for FFPE tissues

• Incubation: Typically 1-2 hours at room temperature or overnight at 4°C

• Detection System: Follow manufacturer's recommendations for the specific detection kit

ELISA:

• Starting Dilution: 1:100 to 1:500 (optimize through titration)

• Incubation Time: 1-2 hours at room temperature

• Temperature: Most assays perform optimally at room temperature (25°C)

Immunofluorescence:

• Recommended Dilution: 1:100 has been suggested for immunofluorescence labeling

• Incubation: 1-2 hours at room temperature or overnight at 4°C

• Secondary Antibody: Select fluorophore-conjugated antibodies appropriate for your imaging system

For all applications, researchers should perform titration experiments to determine optimal conditions for their specific experimental system, as factors such as tissue type, fixation method, and protein abundance can significantly impact performance.

What are the common troubleshooting issues in Western blot detection of SLC5A9?

When troubleshooting Western blot detection of SLC5A9, researchers should consider these common issues and solutions:

No Signal:

• Verify SLC5A9 expression in sample type

• Check protein transfer efficiency

• Increase antibody concentration

• Extend exposure time

• Use enhanced chemiluminescence detection system

• Evaluate need for membrane protein enrichment

Multiple Bands:

• Consider post-translational modifications

• Evaluate potential protein degradation

• Test alternative antibodies targeting different epitopes

• Increase wash stringency

• Optimize blocking conditions

High Background:

• Decrease antibody concentration

• Increase blocking time or concentration

• Add Tween-20 to wash buffers (0.1-0.3%)

• Increase number and duration of washes

• Use fresh blocking reagents

• Consider alternative membrane types

Weak Signal:

• Increase sample loading

• Decrease dilution of primary antibody

• Extend primary antibody incubation time

• Consider signal enhancement methods

• Evaluate protein extraction efficiency for membrane proteins

What is the troubleshooting decision tree for ELISA using SLC5A9 antibodies?

ELISA troubleshooting for SLC5A9 detection follows a structured approach based on the observed issues:

How do I resolve inconsistent staining patterns in IHC using SLC5A9 antibodies?

Inconsistent immunohistochemical staining with SLC5A9 antibodies can be addressed through systematic optimization:

Antigen Retrieval Optimization:

• Test multiple antigen retrieval methods (heat vs. enzymatic)

• Vary buffer composition (citrate, EDTA, Tris)

• Adjust retrieval time and temperature

Fixation Considerations:

• Standardize fixation time for all samples

• Consider the impact of over-fixation on epitope accessibility

• Test fresh-frozen sections if formalin-fixed tissues give inconsistent results

Antibody Optimization:

• Titrate antibody concentration using positive control tissues

• Compare different antibody clones targeting distinct epitopes

• Consider the use of amplification systems for low-abundance targets

Detection System Variables:

• Standardize incubation times for detection reagents

• Use automated staining platforms for improved consistency

• Evaluate different detection chemistries (HRP vs. AP)

Tissue Handling:

• Minimize section drying during staining process

• Use hydrophobic barriers to ensure reagent coverage

• Standardize all washing steps

How can I increase sensitivity when detecting low-abundance SLC5A9 in samples?

Detecting low-abundance SLC5A9 may require specialized approaches to enhance sensitivity:

For Western Blotting:

• Enrich membrane proteins through ultracentrifugation or commercial kits

• Use high-sensitivity chemiluminescent substrates

• Consider signal enhancement systems

• Increase sample loading while maintaining good resolution

• Use PVDF membranes with higher protein binding capacity

• Extend primary antibody incubation (overnight at 4°C)

For Immunohistochemistry:

• Implement tyramide signal amplification (TSA) or other amplification systems

• Optimize antigen retrieval conditions extensively

• Use polymer-based detection systems instead of traditional ABC methods

• Consider automated platforms with optimized protocols

• Use higher antibody concentrations with reduced incubation times

For ELISA:

• Consider sandwich ELISA format for improved sensitivity

• Implement signal amplification methods

• Extend substrate incubation time (while monitoring background)

• Reduce sample dilution where possible

• Optimize plate washing to retain maximum signal

• Consider alternative detection methods (fluorescence, chemiluminescence)